Unlocking new possibilities for the treatment of fibrotic diseases
Explore Our Science
Endeavor BioMedicines is a clinical-stage biotechnology company focused on developing medicines for the treatment of fibrotic diseases with high unmet need. By unlocking the therapeutic potential of the Hedgehog (Hh) signaling pathway, Endeavor is advancing a new approach to addressing fibrosis across organ systems. The company’s initial focus is on the development of its lead investigational candidate, taladegib (ENV-101), an inhibitor of the Hh signaling pathway in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF).
OUR SCIENCE
Our scientific research is focused on addressing the biology that drives fibrotic disease progression. The Hedgehog signaling pathway represents a novel approach to target the causative cellular drivers of fibrotic diseases.
Our leadership team has deep experience in translating scientific innovation into medicines that make a meaningful difference for patients, including those affected by serious diseases with high unmet need.
OUR LEADERSHIP
OUR CULTURE
We have a vibrant and passionate culture that reflects our shared mission to deliver new therapeutic options for patients affected by serious diseases with high unmet need.
LATEST NEWS
Endeavor BioMedicines’ WHISTLE-PF Phase 2b Trial of Taladegib Meets Primary and Key Secondary Endpoints in Patients with IPF
WHISTLE-PF trial met its primary endpoint, demonstrating a statistically significant improvement in lung function (percent predicted forced vital capacity - ppFVC) compared to placebo; data to be presented at future medical meeting The trial demonstrated statistical significance for multiple secondary endpoints compared to placebo, including reduced lung fibrosis and increased total...
Endeavor BioMedicines Presents New Quantitative Imaging Data from Analysis of Phase 2a Clinical Trial Evaluating Taladegib (ENV-101) in Patients with Idiopathic Pulmonary Fibrosis
Findings presented at the European Respiratory Society Congress 2026 corroborate previous findings and provide continued clinical evidence supporting taladegib SAN DIEGO - September 8, 2026 - Endeavor BioMedicines ("Endeavor"), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today presented a...
Endeavor BioMedicines to Present Quantitative Image Analysis from Phase 2a Trial of Taladegib (ENV-101) at European Respiratory Society (ERS) Congress 2026
SAN DIEGO – August 25, 2026 – Endeavor BioMedicines ("Endeavor"), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced that results from a High-Resolution Computed Tomography (HRCT) post hoc analysis from its Phase 2a trial evaluating taladegib (ENV-101) in...
Fibrotic Lung Disease
Phase 2b WHISTLE-PF trial met its primary and multiple secondary endpoints, supporting continued investigation of Hedgehog pathway inhibition as a potential approach to addressing fibrosis.